Selective kinase inhibitors as tools for neuroscience research

Neuropharmacology

Volumn 63, Issue 7, 2012, Pages 1227-1237

  Martin, Kirsty J ^a   Arthur, J Simon C ^b  

^a HERIOT WATT UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Kinase inhibitor; Signaling; Small molecule

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NERVE GROWTH FACTOR; NEUROTRANSMITTER; NEUROTROPHIN; NEUROTROPHIN 3; NEUROTROPHIN 4; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE C; PROTEIN KINASE C ZETA; PROTEIN KINASE INHIBITOR;

CELL GROWTH; CELL SURVIVAL; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LONG TERM POTENTIATION; MEDICAL RESEARCH; NERVE CELL; NERVE CELL NECROSIS; NEUROSCIENCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BRAIN; NEURONS; NEUROSCIENCES; PROTEIN KINASE INHIBITORS; RESEARCH; SIGNAL TRANSDUCTION;

EID: 84866038981     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2012.07.024     Document Type: Review

References (206)

1. A. Abeliovich, C. Chen, Y. Goda, A.J. Silva, C.F. Stevens, and S. Tonegawa Modified hippocampal long-term potentiation in PKC gamma-mutant mice Cell 75 1993 1253 1262
2. A. Abeliovich, R. Paylor, C. Chen, J.J. Kim, J.M. Wehner, and S. Tonegawa PKC gamma mutant mice exhibit mild deficits in spatial and contextual learning Cell 75 1993 1263 1271
3. D.R. Alessi, A. Cuenda, P. Cohen, D.T. Dudley, and A.R. Saltiel PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo J. Biol. Chem. 270 1995 27489 27494
4. T. Anastassiadis, S.W. Deacon, K. Devarajan, H. Ma, and J.R. Peterson Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity Nat. Biotechnol. 29 2011 1039 1045
5. R. Anjum, and J. Blenis The RSK family of kinases: emerging roles in cellular signaling Nat. Rev. Mol. Cell. Biol. 9 2008 747 758
6. M. Aouadi, F. Bost, L. Caron, K. Laurent, Y. Le Marchand Brustel, and B. Binetruy p38 mitogen-activated protein kinase activity commits embryonic stem cells to either neurogenesis or cardiomyogenesis Stem Cells 24 2006 1399 1406
7. M.A. Arslan, O. Kutuk, and H. Basaga Protein kinases as drug targets in cancer Curr. Cancer Drug Targets 6 2006 623 634
8. J.S. Arthur, A.L. Fong, J.M. Dwyer, M. Davare, E. Reese, K. Obrietan, and S. Impey Mitogen- and stress-activated protein kinase 1 mediates cAMP response element-binding protein phosphorylation and activation by neurotrophins J. Neurosci. 24 2004 4324 4332
9. B. Ataman, J. Ashley, M. Gorczyca, P. Ramachandran, W. Fouquet, S.J. Sigrist, and V. Budnik Rapid activity-dependent modifications in synaptic structure and function require bidirectional Wnt signaling Neuron 57 2008 705 718
10. J. Bain, H. McLauchlan, M. Elliott, and P. Cohen The specificities of protein kinase inhibitors: an update Biochem. J. 371 2003 199 204
11. J. Bain, L. Plater, M. Elliott, N. Shpiro, C.J. Hastie, H. McLauchlan, I. Klevernic, J.S. Arthur, D.R. Alessi, and P. Cohen The selectivity of protein kinase inhibitors: a further update Biochem. J. 408 2007 297 315
12. J.A. Beavo, P.J. Bechtel, and E.G. Krebs Mechanisms of control for cAMP-dependent protein kinase from skeletal muscle Adv. Cyclic Nucleotide Res. 5 1975 241 251
13. P.H. Bernardo, K.F. Wan, T. Sivaraman, J. Xu, F.K. Moore, A.W. Hung, H.Y. Mok, V.C. Yu, and C.L. Chai Structure-activity relationship studies of phenanthridine-based Bcl-XL inhibitors J. Med. Chem. 51 2008 6699 6710
14. A. Bishop, O. Buzko, S. Heyeck-Dumas, I. Jung, B. Kraybill, Y. Liu, K. Shah, S. Ulrich, L. Witucki, F. Yang, C. Zhang, and K.M. Shokat Unnatural ligands for engineered proteins: new tools for chemical genetics Annu. Rev. Biophys. Biomol. Struct. 29 2000 577 606
15. A.C. Bishop, J.A. Ubersax, D.T. Petsch, D.P. Matheos, N.S. Gray, J. Blethrow, E. Shimizu, J.Z. Tsien, P.G. Schultz, M.D. Rose, J.L. Wood, D.O. Morgan, and K.M. Shokat A chemical switch for inhibitor-sensitive alleles of any protein kinase Nature 407 2000 395 401
16. K.M. Bisset, A.S. Dhopeshwarkar, C. Liao, and R.A. Nicholson The G protein-coupled cannabinoid-1 (CB1) receptor of mammalian brain: inhibition by phthalate esters in vitro Neurochem. Int. 59 2011 706 713
17. P.D. Boasberg, C.H. Redfern, G.A. Daniels, D. Bodkin, C.R. Garrett, and A.D. Ricart Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer Cancer Chemother. Pharmacol. 68 2011 547 552
18. M.G. Bonilla-Hernan, M.E. Miranda-Carus, and E. Martin-Mola New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors Rheumatology (Oxf.) 50 2011 1542 1550
19. B.J. Bowers, A.C. Collins, T. Tritto, and J.M. Wehner Mice lacking PKC gamma exhibit decreased anxiety Behav. Genet. 30 2000 111 121
20. O. Bozdagi, E. Rich, S. Tronel, M. Sadahiro, K. Patterson, M.L. Shapiro, C.M. Alberini, G.W. Huntley, and S.R. Salton The neurotrophin-inducible gene Vgf regulates hippocampal function and behavior through a brain-derived neurotrophic factor-dependent mechanism J. Neurosci. 28 2008 9857 9869
21. K. Brami-Cherrier, E. Valjent, D. Herve, J. Darragh, J.C. Corvol, C. Pages, S.J. Arthur, J.A. Girault, and J. Caboche Parsing molecular and behavioral effects of cocaine in mitogen- and stress-activated protein kinase-1-deficient mice J. Neurosci. 25 2005 11444 11454
22. S.R. Bruckner, S.P. Tammariello, C.Y. Kuan, R.A. Flavell, P. Rakic, and S. Estus JNK3 contributes to c-Jun activation and apoptosis but not oxidative stress in nerve growth factor-deprived sympathetic neurons J. Neurochem. 78 2001 298 303
23. I. Buard, S.J. Coultrap, R.K. Freund, Y.S. Lee, M.L. Dell'Acqua, A.J. Silva, and K.U. Bayer CaMKII "autonomy" is required for initiating but not for maintaining neuronal long-term information storage J. Neurosci. 30 2010 8214 8220
24. D. Cai, K. Pearce, S. Chen, and D.L. Glanzman Protein kinase M maintains long-term sensitization and long-term facilitation in aplysia J. Neurosci. 31 2011 6421 6431
25. Y. Chandramohan, S.K. Droste, J.S. Arthur, and J.M. Reul The forced swimming-induced behavioural immobility response involves histone H3 phospho-acetylation and c-Fos induction in dentate gyrus granule neurons via activation of the N-methyl-D-aspartate/extracellular signal-regulated kinase/mitogen- and stress-activated kinase signaling pathway Eur. J. Neurosci. 27 2008 2701 2713
26. J. Chen, C.S. Park, and S.J. Tang Activity-dependent synaptic Wnt release regulates hippocampal long term potentiation J. Biol. Chem. 281 2006 11910 11916
27. W.D. Cheung, and G.W. Hart AMP-activated protein kinase and p38 MAPK activate O-GlcNAcylation of neuronal proteins during glucose deprivation J. Biol. Chem. 283 2008 13009 13020
28. T. Chijiwa, A. Mishima, M. Hagiwara, M. Sano, K. Hayashi, T. Inoue, K. Naito, T. Toshioka, and H. Hidaka Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5- isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells J. Biol. Chem. 265 1990 5267 5272
29. W.B. Chwang, J.S. Arthur, A. Schumacher, and J.D. Sweatt The nuclear kinase mitogen- and stress-activated protein kinase 1 regulates hippocampal chromatin remodeling in memory formation J. Neurosci. 27 2007 12732 12742
30. M.S. Cohen, C. Zhang, K.M. Shokat, and J. Taunton Structural bioinformatics-based design of selective, irreversible kinase inhibitors Science 308 2005 1318 1321
31. P. Cohen Guidelines for the effective use of chemical inhibitors of protein function to understand their roles in cell regulation Biochem. J. 425 2009 53 54
32. P. Cohen Targeting protein kinases for the development of anti-inflammatory drugs Curr. Opin. Cell. Biol. 21 2009 317 324
33. S.L. Constant, C. Dong, D.D. Yang, M. Wysk, R.J. Davis, and R.A. Flavell JNK1 is required for T cell-mediated immunity against Leishmania major infection J. Immunol. 165 2000 2671 2676
34. D. Conze, T. Krahl, N. Kennedy, L. Weiss, J. Lumsden, P. Hess, R.A. Flavell, G. Le Gros, R.J. Davis, and M. Rincon c-Jun NH(2)-terminal kinase (JNK)1 and JNK2 have distinct roles in CD8(+) T cell activation J. Exp. Med. 195 2002 811 823
35. G.D. Dalton, and W.L. Dewey Protein kinase inhibitor peptide (PKI): a family of endogenous neuropeptides that modulate neuronal cAMP-dependent protein kinase function Neuropeptides 40 2006 23 34
36. S.P. Davies, H. Reddy, M. Caivano, and P. Cohen Specificity and mechanism of action of some commonly used protein kinase inhibitors Biochem. J. 351 2000 95 105
37. M.I. Davis, J.P. Hunt, S. Herrgard, P. Ciceri, L.M. Wodicka, G. Pallares, M. Hocker, D.K. Treiber, and P.P. Zarrinkar Comprehensive analysis of kinase inhibitor selectivity Nat. Biotechnol. 29 2011 1046 1051
38. P.D. Davis, C.H. Hill, G. Lawton, J.S. Nixon, S.E. Wilkinson, S.A. Hurst, E. Keech, and S.E. Turner Inhibitors of protein kinase C. 1. 2,3-bisarylmaleimides J. Med. Chem. 35 1992 177 184
39. R.J. de Wit, D. Hekstra, B. Jastorff, W.J. Stec, J. Baraniak, R. Van Driel, and P.J. Van Haastert Inhibitory action of certain cyclophosphate derivatives of cAMP on cAMP-dependent protein kinases Eur. J. Biochem. 142 1984 255 260
40. X. Deng, N. Dzamko, A. Prescott, P. Davies, Q. Liu, Q. Yang, J.D. Lee, M.P. Patricelli, T.K. Nomanbhoy, D.R. Alessi, and N.S. Gray Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2 Nat. Chem. Biol. 7 2011 203 205
41. C. Dong, D.D. Yang, M. Wysk, A.J. Whitmarsh, R.J. Davis, and R.A. Flavell Defective T cell differentiation in the absence of Jnk1 Science 282 1998 2092 2095
42. J.M. Dong, T. Leung, E. Manser, and L. Lim cAMP-induced morphological changes are counteracted by the activated RhoA small GTPase and the Rho kinase ROKalpha J. Biol. Chem. 273 1998 22554 22562
43. W.R. Dostmann (RP)-cAMPS inhibits the cAMP-dependent protein kinase by blocking the cAMP-induced conformational transition FEBS Lett. 375 1995 231 234
44. E.A. Drier, M.K. Tello, M. Cowan, P. Wu, N. Blace, T.C. Sacktor, and J.C. Yin Memory enhancement and formation by atypical PKM activity in Drosophila melanogaster Nat. Neurosci. 5 2002 316 324
45. J. Drsata, J. Ulrichova, and D. Walterova Sanguinarine and chelerythrine as inhibitors of aromatic amino acid decarboxylase J. Enzym. Inhib. 10 1996 231 237
46. P. Duffy, A. Schmandke, J. Sigworth, S. Narumiya, W.B. Cafferty, and S.M. Strittmatter Rho-associated kinase II (ROCKII) limits axonal growth after trauma within the adult mouse spinal cord J. Neurosci. 29 2009 15266 15276
47. M.J. During, and L. Cao VEGF, a mediator of the effect of experience on hippocampal neurogenesis Curr. Alzheimer Res. 3 2006 29 33
48. T. Eichholtz, D.B. de Bont, J. de Widt, R.M. Liskamp, and H.L. Ploegh A myristoylated pseudo-substrate peptide, a novel protein kinase C inhibitor J. Biol. Chem. 268 1993 1982 1986
49. J.E. Engel, X.J. Xie, M.B. Sokolowski, and C.F. Wu A cGMP-dependent protein kinase gene, foraging, modifies habituation-like response decrement of the giant fiber escape circuit in Drosophila Learn. Mem. 7 2000 341 352
50. R.A. Engh, A. Girod, V. Kinzel, R. Huber, and D. Bossemeyer Crystal structures of catalytic subunit of cAMP-dependent protein kinase in complex with isoquinolinesulfonyl protein kinase inhibitors H7, H8, and H89. Structural implications for selectivity J. Biol. Chem. 271 1996 26157 26164
51. 2+/calmodulin-dependent protein kinase IV. Role in transcriptional regulation J. Biol. Chem. 269 1994 15520 15527
52. P.A. Eyers, I.P. van den, R.A. Quinlan, M. Goedert, and P. Cohen Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580 FEBS Lett. 451 1999 191 196
53. M.A. Fabian, W.H. Biggs 3rd, D.K. Treiber, C.E. Atteridge, M.D. Azimioara, M.G. Benedetti, T.A. Carter, P. Ciceri, P.T. Edeen, M. Floyd, J.M. Ford, M. Galvin, J.L. Gerlach, R.M. Grotzfeld, S. Herrgard, D.E. Insko, M.A. Insko, A.G. Lai, J.M. Lelias, S.A. Mehta, Z.V. Milanov, A.M. Velasco, L.M. Wodicka, H.K. Patel, P.P. Zarrinkar, and D.J. Lockhart A small molecule-kinase interaction map for clinical kinase inhibitors Nat. Biotechnol. 23 2005 329 336
54. M.F. Favata, K.Y. Horiuchi, E.J. Manos, A.J. Daulerio, D.A. Stradley, W.S. Feeser, D.E. Van Dyk, W.J. Pitts, R.A. Earl, F. Hobbs, R.A. Copeland, R.L. Magolda, P.A. Scherle, and J.M. Trzaskos Identification of a novel inhibitor of mitogen-activated protein kinase kinase J. Biol. Chem. 273 1998 18623 18632
55. O. Fedorov, B. Marsden, V. Pogacic, P. Rellos, S. Muller, A.N. Bullock, J. Schwaller, M. Sundstrom, and S. Knapp A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases Proc. Natl. Acad. Sci. U. S. A. 104 2007 20523 20528
56. M.E. Feldman, and K.M. Shokat New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signalling from a new generation of Tor kinase domain inhibitors (TORKinibs) Curr. Top. Microbiol. Immunol. 347 2010 241 262
57. S.S. Gaundar, and L.J. Bendall The potential and limitations of p38MAPK as a drug target for the treatment of hematological malignancies Curr. Drug Targets 11 2010 823 833
58. M.C. Genovese Inhibition of p38: has the fat lady sung? Arthritis Rheum. 60 2009 317 320
59. K. Ghoreschi, A. Laurence, and J.J. O'Shea Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat. Immunol. 10 2009 356 360
60. A.G. Gilmartin, M.R. Bleam, A. Groy, K.G. Moss, E.A. Minthorn, S.G. Kulkarni, C.M. Rominger, S. Erskine, K.E. Fisher, J. Yang, F. Zappacosta, R. Annan, D. Sutton, and S.G. Laquerre GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition Clin. Cancer Res. 17 2011 989 1000
61. D.D. Ginty, and R.A. Segal Retrograde neurotrophin signalling: Trk-ing along the axon Curr. Opin. Neurobiol. 12 2002 268 274
62. B.T. Gjertsen, G. Mellgren, A. Otten, E. Maronde, H.G. Genieser, B. Jastorff, O.K. Vintermyr, G.S. McKnight, and S.O. Doskeland Novel (Rp)-cAMPS analogs as tools for inhibition of cAMP-kinase in cell culture. Basal cAMP-kinase activity modulates interleukin-1 beta action J. Biol. Chem. 270 1995 20599 20607
63. D.B. Glass, M.J. Feller, L.R. Levin, and D.A. Walsh Structural basis for the low affinities of yeast cAMP-dependent and mammalian cGMP-dependent protein kinases for protein kinase inhibitor peptides Biochemistry 31 1992 1728 1734
64. R. Gong, C. Ding, J. Hu, Y. Lu, F. Liu, E. Mann, F. Xu, M.B. Cohen, and M. Luo Role for the membrane receptor guanylyl cyclase-C in attention deficiency and hyperactive behavior Science 2011
65. G.A. Gonzalez, and M.R. Montminy Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133 Cell 59 1989 675 680
66. M. Gooney, and M.A. Lynch Long-term potentiation in the dentate gyrus of the rat hippocampus is accompanied by brain-derived neurotrophic factor-induced activation of TrkB J. Neurochem. 77 2001 1198 1207
67. J.R. Graff, A.M. McNulty, K.R. Hanna, B.W. Konicek, R.L. Lynch, S.N. Bailey, C. Banks, A. Capen, R. Goode, J.E. Lewis, L. Sams, K.L. Huss, R.M. Campbell, P.W. Iversen, B.L. Neubauer, T.J. Brown, L. Musib, S. Geeganage, and D. Thornton The protein kinase Cbeta-selective inhibitor, enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts Cancer Res. 65 2005 7462 7469
68. R. Gopalakrishna, Z.H. Chen, and U. Gundimeda Irreversible oxidative inactivation of protein kinase C by photosensitive inhibitor calphostin C FEBS Lett. 314 1992 149 154
69. C. Grothe, and M. Timmer The physiological and pharmacological role of basic fibroblast growth factor in the dopaminergic nigrostriatal system Brain Res. Rev. 54 2007 80 91
70. P. Gubellini, Y. Ben-Ari, and J.L. Gaiarsa Endogenous neurotrophins are required for the induction of GABAergic long-term potentiation in the neonatal rat hippocampus J. Neurosci. 25 2005 5796 5802
71. F. Guillemot, and C. Zimmer From cradle to grave: the multiple roles of fibroblast growth factors in neural development Neuron 71 2011 574 588
72. A.C. Hall, A. Brennan, R.G. Goold, K. Cleverley, F.R. Lucas, P.R. Gordon-Weeks, and P.C. Salinas Valproate regulates GSK-3-mediated axonal remodeling and synapsin I clustering in developing neurons Mol. Cell. Neurosci. 20 2002 257 270
73. Y. Han, M. Lamb, P. Mohr, D. Yu, B. Wang, and T. Wang 4-(3-Aminopyrazole) Pyrimidine Derivatives for Use as Tyrosine Kinase Inhibitors in the Treatment of Cancer 2006
74. T.E. Harris, S.J. Persaud, and P.M. Jones Pseudosubstrate inhibition of cyclic AMP-dependent protein kinase in intact pancreatic islets: effects on cyclic AMP-dependent and glucose-dependent insulin secretion Biochem. Biophys. Res. Commun. 232 1997 648 651
75. H.C. Hartzell, and A. Rinderknecht Calphostin C, a widely used protein kinase C inhibitor, directly and potently blocks L-type Ca channels Am. J. Physiol. 270 1996 C1293 C1299
76. K.H. Harum, L. Alemi, and M.V. Johnston Cognitive impairment in Coffin-Lowry syndrome correlates with reduced RSK2 activation Neurology 56 2001 207 214
77. S.A. Hawley, D.A. Pan, K.J. Mustard, L. Ross, J. Bain, A.M. Edelman, B.G. Frenguelli, and D.G. Hardie Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase Cell. Metab. 2 2005 9 19
78. L.E. Heasley, and S.Y. Han JNK regulation of oncogenesis Mol. Cells 21 2006 167 173
79. J.M. Herbert, J.M. Augereau, J. Gleye, and J.P. Maffrand Chelerythrine is a potent and specific inhibitor of protein kinase C Biochem. Biophys. Res. Commun. 172 1990 993 999
80. A.I. Hernandez, N. Blace, J.F. Crary, P.A. Serrano, M. Leitges, J.M. Libien, G. Weinstein, A. Tcherapanov, and T.C. Sacktor Protein kinase M zeta synthesis from a brain mRNA encoding an independent protein kinase C zeta catalytic domain. Implications for the molecular mechanism of memory J. Biol. Chem. 278 2003 40305 40316
81. E.O. Hexner, C. Serdikoff, M. Jan, C.R. Swider, C. Robinson, S. Yang, T. Angeles, S.G. Emerson, M. Carroll, B. Ruggeri, and P. Dobrzanski Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders Blood 111 2008 5663 5671
82. M.L. Hixon, L. Paccagnella, R. Millham, R. Perez-Olle, and A. Gualberto Development of inhibitors of the IGF-IR/PI3K/Akt/mTOR pathway Rev. Recent Clin. Trials 5 2010 189 208
83. J. Hofmann The potential for isoenzyme-selective modulation of protein kinase C FASEB J. 11 1997 649 669
84. G.G. Holz, O.G. Chepurny, and F. Schwede Epac-selective cAMP analogs: new tools with which to evaluate the signal transduction properties of cAMP-regulated guanine nucleotide exchange factors Cell. Signal. 20 2008 10 20
85. S. Hrabetova, and T.C. Sacktor Bidirectional regulation of protein kinase M zeta in the maintenance of long-term potentiation and long-term depression J. Neurosci. 16 1996 5324 5333
86. S. Hrabetova, and T.C. Sacktor Transient translocation of conventional protein kinase C isoforms and persistent downregulation of atypical protein kinase Mzeta in long-term depression Brain Res. Mol. Brain Res. 95 2001 146 152
87. E.J. Huang, and L.F. Reichardt Neurotrophins: roles in neuronal development and function Annu. Rev. Neurosci. 24 2001 677 736
88. S. Hunot, M. Vila, P. Teismann, R.J. Davis, E.C. Hirsch, S. Przedborski, P. Rakic, and R.A. Flavell JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease Proc. Natl. Acad. Sci. U. S. A. 101 2004 665 670
89. O. Hvalby, H.C. Hemmings Jr. , O. Paulsen, A.J. Czernik, A.C. Nairn, J.M. Godfraind, V. Jensen, M. Raastad, J.F. Storm, and P. Andersen Specificity of protein kinase inhibitor peptides and induction of long-term potentiation Proc. Natl. Acad. Sci. U. S. A. 91 1994 4761 4765
90. T. Iida, E. Kobayashi, M. Yoshida, and H. Sano Calphostins, novel and specific inhibitors of protein kinase C. II. Chemical structures J. Antibiot. (Tokyo) 42 1989 1475 1481
91. 2+ stimulation of CREB-dependent transcription and ERK nuclear translocation Neuron 21 1998 869 883
92. S. Jacquot, M. Zeniou, R. Touraine, and A. Hanauer X-linked Coffin-Lowry syndrome (CLS, MIM 303600, RPS6KA3 gene, protein product known under various names: pp90(rsk2), RSK2, ISPK, MAPKAP1) Eur. J. Hum. Genet. 10 2002 2 5
93. F. Jursky, and M. Baliova Differential effect of the benzophenanthridine alkaloids sanguinarine and chelerythrine on glycine transporters Neurochem. Int. 58 2011 641 647
94. H. Kaneto The JNK pathway as a therapeutic target for diabetes Expert Opin. Ther. Targets 9 2005 581 592
95. M.W. Karaman, S. Herrgard, D.K. Treiber, P. Gallant, C.E. Atteridge, B.T. Campbell, K.W. Chan, P. Ciceri, M.I. Davis, P.T. Edeen, R. Faraoni, M. Floyd, J.P. Hunt, D.J. Lockhart, Z.V. Milanov, M.J. Morrison, G. Pallares, H.K. Patel, S. Pritchard, L.M. Wodicka, and P.P. Zarrinkar A quantitative analysis of kinase inhibitor selectivity Nat. Biotechnol. 26 2008 127 132
96. H. Kase, K. Iwahashi, and Y. Matsuda K-252a, a potent inhibitor of protein kinase C from microbial origin J. Antibiot. (Tokyo) 39 1986 1059 1065
97. H. Kase, K. Iwahashi, S. Nakanishi, Y. Matsuda, K. Yamada, M. Takahashi, C. Murakata, A. Sato, and M. Kaneko K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases Biochem. Biophys. Res. Commun. 142 1987 436 440
98. S.H. Kim, J.S. Tokarski, K.J. Leavitt, B.E. Fink, M.E. Salvati, R. Moquin, M.T. Obermeier, G.L. Trainor, G.G. Vite, L.K. Stadnick, J.S. Lippy, D. You, M.V. Lorenzi, and P. Chen Identification of 2-amino-5-(thioaryl)thiazoles as inhibitors of nerve growth factor receptor TrkA Bioorg. Med. Chem. Lett. 18 2008 634 639
99. Z.A. Knight Small molecule inhibitors of the PI3-kinase family Curr. Top. Microbiol. Immunol. 347 2010 263 278
100. S. Koizumi, M.L. Contreras, Y. Matsuda, T. Hama, P. Lazarovici, and G. Guroff K-252a: a specific inhibitor of the action of nerve growth factor on PC 12 cells J. Neurosci. 8 1988 715 721
101. Y. Kuma, G. Sabio, J. Bain, N. Shpiro, R. Marquez, and A. Cuenda BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo J. Biol. Chem. 280 2005 19472 19479
102. D. Lambrechts, and P. Carmeliet VEGF at the neurovascular interface: therapeutic implications for motor neuron disease Biochim. Biophys. Acta 1762 2006 1109 1121
103. C. Laudanna, D. Mochly-Rosen, T. Liron, G. Constantin, and E.C. Butcher Evidence of zeta protein kinase C involvement in polymorphonuclear neutrophil integrin-dependent adhesion and chemotaxis J. Biol. Chem. 273 1998 30306 30315
104. M.A. Lawlor, A. Mora, P.R. Ashby, M.R. Williams, V. Murray-Tait, L. Malone, A.R. Prescott, J.M. Lucocq, and D.R. Alessi Essential role of PDK1 in regulating cell size and development in mice EMBO J. 21 2002 3728 3738
105. + channels in vascular myocytes J. Pharmacol. Exp. Ther. 290 1999 1165 1174
106. J. Leemhuis, S. Boutillier, G. Schmidt, and D.K. Meyer The protein kinase A inhibitor H89 acts on cell morphology by inhibiting Rho kinase J. Pharmacol. Exp. Ther. 300 2002 1000 1007
107. F. Lemtiri-Chlieh, and E.S. Levine BDNF evokes release of endogenous cannabinoids at layer 2/3 inhibitory synapses in the neocortex J. Neurophysiol. 104 2010 1923 1932
108. H.M. Lesscher, T. McMahon, A.W. Lasek, W.H. Chou, J. Connolly, V. Kharazia, and R.O. Messing Amygdala protein kinase C epsilon regulates corticotropin-releasing factor and anxiety-like behavior Genes Brain Behav. 7 2008 323 333
109. H.M. Lesscher, M.J. Wallace, L. Zeng, V. Wang, J.K. Deitchman, T. McMahon, R.O. Messing, and P.M. Newton Amygdala protein kinase C epsilon controls alcohol consumption Genes Brain Behav. 8 2009 493 499
110. M. Levis, J. Allebach, K.F. Tse, R. Zheng, B.R. Baldwin, B.D. Smith, S. Jones-Bolin, B. Ruggeri, C. Dionne, and D. Small A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo Blood 99 2002 3885 3891
111. 2+ channels Mol. Pharmacol. 42 1992 488 489
112. D.S. Ling, L.S. Benardo, P.A. Serrano, N. Blace, M.T. Kelly, J.F. Crary, and T.C. Sacktor Protein kinase Mzeta is necessary and sufficient for LTP maintenance Nat. Neurosci. 5 2002 295 296
113. Q. Liu, S.A. Kang, C.C. Thoreen, W. Hur, J. Wang, J.W. Chang, A. Markhard, J. Zhang, T. Sim, D.M. Sabatini, and N.S. Gray Development of ATP-competitive mTOR inhibitors Methods Mol. Biol. 821 2012 447 460
114. A. Lochner, and J.A. Moolman The many faces of H89: a review Cardiovasc. Drug Rev. 24 2006 261 274
115. B. Lu, and A. Figurov Role of neurotrophins in synapse development and plasticity Rev. Neurosci. 8 1997 1 12
116. L. Malki-Feldman, and C.L. Jaffe Leishmania major: effect of protein kinase A and phosphodiesterase activity on infectivity and proliferation of promastigotes Exp. Parasitol. 123 2009 39 44
117. G. Manning, G.D. Plowman, T. Hunter, and S. Sudarsanam Evolution of protein kinase signalling from yeast to man Trends Biochem. Sci. 27 2002 514 520
118. G. Manning, D.B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam The protein kinase complement of the human genome Science 298 2002 1912 1934
119. B.S. Marshall, G. Price, and C.T. Powell Rat protein kinase c zeta gene contains alternative promoters for generation of dual transcripts with 5′-end heterogeneity DNA Cell. Biol. 19 2000 707 719
120. K.J. Martin, N. Shpiro, R. Traynor, M. Elliott, and J.S. Arthur Comparison of the specificity of Trk inhibitors in recombinant and neuronal assays Neuropharmacology 61 2011 148 155
121. S.S. Matkar, L.A. Wrischnik, and U. Hellmann-Blumberg Production of hydrogen peroxide and redox cycling can explain how sanguinarine and chelerythrine induce rapid apoptosis Arch. Biochem. Biophys. 477 2008 43 52
122. L.D. McCullough, Z. Zeng, H. Li, L.E. Landree, J. McFadden, and G.V. Ronnett Pharmacological inhibition of AMP-activated protein kinase provides neuroprotection in stroke J. Biol. Chem. 280 2005 20493 20502
123. S.J. Miknyoczki, C.A. Dionne, A.J. Klein-Szanto, and B.A. Ruggeri The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness Ann. N. Y Acad. Sci. 880 1999 252 262
124. L. Minichiello TrkB signalling pathways in LTP and learning Nat. Rev. Neurosci. 10 2009 850 860
125. J.E. Minturn, A.E. Evans, J.G. Villablanca, G.A. Yanik, J.R. Park, S. Shusterman, S. Groshen, E.T. Hellriegel, D. Bensen-Kennedy, K.K. Matthay, G.M. Brodeur, and J.M. Maris Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study Cancer Chemother. Pharmacol. 68 2011 1057 1065
126. 2+/calmodulin-dependent protein kinase V from rat cerebrum J. Biol. Chem. 268 1993 9143 9147
127. D. Moncada, and H. Viola PKMzeta inactivation induces spatial familiarity Learn. Mem. 15 2008 810 814
128. L. Munoz, and A.J. Ammit Targeting p38 MAPK pathway for the treatment of Alzheimer's disease Neuropharmacology 58 2010 561 568
129. A.J. Murray Pharmacological PKA inhibition: all may not be what it seems Sci. Signal. 1 2008 re4
130. S. Nakanishi, Y. Matsuda, K. Iwahashi, and H. Kase K-252b, c and d, potent inhibitors of protein kinase C from microbial origin J. Antibiot. (Tokyo) 39 1986 1066 1071
131. H. Nakano, E. Kobayashi, I. Takahashi, T. Tamaoki, Y. Kuzuu, and H. Iba Staurosporine inhibits tyrosine-specific protein kinase activity of Rous sarcoma virus transforming protein p60 J. Antibiot. (Tokyo) 40 1987 706 708
132. S. Naqvi, A. Macdonald, C.E. McCoy, J. Darragh, A.D. Reith, and J.S. Arthur Characterization of the cellular action of the MSK inhibitor SB-747651A Biochem. J. 441 2012 347 357
133. A.C. Newton Protein kinase C: poised to signal Am. J. Physiol. Endocrinol. Metab. 298 2010 E395 E402
134. A. Nykjaer, T.E. Willnow, and C.M. Petersen p75NTR-live or let die Curr. Opin. Neurobiol. 15 2005 49 57
135. Y. Obara, and N. Nakahata The signalling pathway leading to extracellular signal-regulated kinase 5 (ERK5) activation via G-proteins and ERK5-dependent neurotrophic effects Mol. Pharmacol. 77 2010 10 16
136. P. Osten, L. Valsamis, A. Harris, and T.C. Sacktor Protein synthesis-dependent formation of protein kinase Mzeta in long-term potentiation J. Neurosci. 16 1996 2444 2451
137. H. Oster, G. Eichele, and M. Leitges Differential expression of atypical PKCs in the adult mouse brain Brain Res. Mol. Brain Res. 127 2004 79 88
138. P.J. Parker, and J. Murray-Rust PKC at a glance J. Cell. Sci. 117 2004 131 132
139. L.H. Pettus, and R.P. Wurz Small molecule p38 MAP kinase inhibitors for the treatment of inflammatory diseases: novel structures and developments during 2006-2008 Curr. Top. Med. Chem. 8 2008 1452 1467
140. R. Poirier, S. Jacquot, C. Vaillend, A.A. Soutthiphong, M. Libbey, S. Davis, S. Laroche, A. Hanauer, H. Welzl, H.P. Lipp, and D.P. Wolfer Deletion of the Coffin-Lowry syndrome gene Rsk2 in mice is associated with impaired spatial learning and reduced control of exploratory behavior Behav. Genet. 37 2007 31 50
141. N.P. Poolos, J.B. Bullis, and M.K. Roth Modulation of h-channels in hippocampal pyramidal neurons by p38 mitogen-activated protein kinase J. Neurosci. 26 2006 7995 8003
142. C.M. Powell, D. Johnston, and J.D. Sweatt Autonomously active protein kinase C in the maintenance phase of N-methyl-D-aspartate receptor-independent long term potentiation J. Biol. Chem. 269 1994 27958 27963
143. L.F. Reichardt Neurotrophin-regulated signalling pathways Philos. Trans. R. Soc. Lond. B Biol. Sci. 361 2006 1545 1564
144. S. Rezazadeh, T.W. Claydon, and D. Fedida KN-93 (2-[N-(2-hydroxyethyl)]- N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinn amyl)-N-methylbenzylamine), a calcium/calmodulin-dependent protein kinase II inhibitor, is a direct extracellular blocker of voltage-gated potassium channels J. Pharmacol. Exp. Ther. 317 2006 292 299
145. J. Roffey, C. Rosse, M. Linch, A. Hibbert, N.Q. McDonald, and P.J. Parker Protein kinase C intervention: the state of play Curr. Opin. Cell. Biol. 21 2009 268 279
146. Y. Romeo, X. Zhang, and P.P. Roux Regulation and function of the RSK family of protein kinases Biochem. J. 441 2011 553 569
147. H. Rosch, R. Schweigreiter, T. Bonhoeffer, Y.A. Barde, and M. Korte The neurotrophin receptor p75NTR modulates long-term depression and regulates the expression of AMPA receptor subunits in the hippocampus Proc. Natl. Acad. Sci. U. S. A. 102 2005 7362 7367
148. T.C. Sacktor, and A.A. Fenton Appropriate application of ZIP for PKMzeta inhibition, LTP reversal, and memory erasure Hippocampus 2011
149. T.C. Sacktor, P. Osten, H. Valsamis, X. Jiang, M.U. Naik, and E. Sublette Persistent activation of the zeta isoform of protein kinase C in the maintenance of long-term potentiation Proc. Natl. Acad. Sci. U. S. A. 90 1993 8342 8346
150. G. Salazar, and A. Gonzalez Novel mechanism for regulation of epidermal growth factor receptor endocytosis revealed by protein kinase A inhibition Mol. Biol. Cell. 13 2002 1677 1693
151. G.P. Sapkota, L. Cummings, F.S. Newell, C. Armstrong, J. Bain, M. Frodin, M. Grauert, M. Hoffmann, G. Schnapp, M. Steegmaier, P. Cohen, and D.R. Alessi BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo Biochem. J. 401 2007 29 38
152. D. Schechtman, and D. Mochly-Rosen Adaptor proteins in protein kinase C-mediated signal transduction Oncogene 20 2001 6339 6347
153. J.S. Sebolt-Leopold Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway Clin. Cancer Res. 14 2008 3651 3656
154. J.S. Sebolt-Leopold, D.T. Dudley, R. Herrera, K. Van Becelaere, A. Wiland, R.C. Gowan, H. Tecle, S.D. Barrett, A. Bridges, S. Przybranowski, W.R. Leopold, and A.R. Saltiel Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo Nat. Med. 5 1999 810 816
155. R.A. Segal Selectivity in neurotrophin signalling: theme and variations Annu. Rev. Neurosci. 26 2003 299 330
156. J.C. Selcher, C.M. Atkins, J.M. Trzaskos, R. Paylor, and J.D. Sweatt A necessity for MAP kinase activation in mammalian spatial learning Learn. Mem. 6 1999 478 490
157. P. Serrano, E.L. Friedman, J. Kenney, S.M. Taubenfeld, J.M. Zimmerman, J. Hanna, C. Alberini, A.E. Kelley, S. Maren, J.W. Rudy, J.C. Yin, T.C. Sacktor, and A.A. Fenton PKMzeta maintains spatial, instrumental, and classically conditioned long-term memories PLoS Biol. 6 2008 2698 2706
158. R. Shema, S. Hazvi, T.C. Sacktor, and Y. Dudai Boundary conditions for the maintenance of memory by PKMzeta in neocortex Learn. Mem. 16 2009 122 128
159. Y. Shi, E. Mantuano, G. Inoue, W.M. Campana, and S.L. Gonias Ligand binding to LRP1 transactivates Trk receptors by a Src family kinase-dependent pathway Sci. Signal. 2 2009 ra18
160. H. Skvara, M. Dawid, E. Kleyn, B. Wolff, J.G. Meingassner, H. Knight, T. Dumortier, T. Kopp, N. Fallahi, G. Stary, C. Burkhart, O. Grenet, J. Wagner, Y. Hijazi, R.E. Morris, C. McGeown, C. Rordorf, C.E. Griffiths, G. Stingl, and T. Jung The PKC inhibitor AEB071 may be a therapeutic option for psoriasis J. Clin. Invest. 118 2008 3151 3159
161. J.A. Smith, D.J. Maloney, S.M. Hecht, and D.A. Lannigan Structural basis for the activity of the RSK-specific inhibitor, SL0101 Bioorg. Med. Chem. 15 2007 5018 5034
162. T.R. Soderling The Ca-calmodulin-dependent protein kinase cascade Trends Biochem. Sci. 24 1999 232 236
163. 2+/calmodulin dependent protein kinase II inhibitor KN-93 reduces dopamine contents in PC12h cells Biochem. Biophys. Res. Commun. 181 1991 968 975
164. ++dependent protein kinase Biochem. Biophys. Res. Commun. 135 1986 397 402
165. I. Tan, J. Lai, J. Yong, S.F. Li, and T. Leung Chelerythrine perturbs lamellar actomyosin filaments by selective inhibition of myotonic dystrophy kinase-related Cdc42-binding kinase FEBS Lett. 585 2011 1260 1268
166. M. Tanaka, S. Sagawa, J. Hoshi, F. Shimoma, I. Matsuda, K. Sakoda, T. Sasase, M. Shindo, and T. Inaba Synthesis of anilino-monoindolylmaleimides as potent and selective PKCbeta inhibitors Bioorg. Med. Chem. Lett. 14 20 2004 Oct 18 5171 5174
167. P. Tapley, F. Lamballe, and M. Barbacid K252a is a selective inhibitor of the tyrosine protein kinase activity of the Trk family of oncogenes and neurotrophin receptors Oncogene 7 1992 371 381
168. R.J. Tatake, M.M. O'Neill, C.A. Kennedy, A.L. Wayne, S. Jakes, D. Wu, S.Z. Kugler Jr. , M.A. Kashem, P. Kaplita, and R.J. Snow Identification of pharmacological inhibitors of the MEK5/ERK5 pathway Biochem. Biophys. Res. Commun. 377 2008 120 125
169. S.L. Taylor, L.M. Stanek, K.J. Ressler, and K.L. Huhman Differential brain-derived neurotrophic factor expression in limbic brain regions following social defeat of territorial aggression Behav. Neurosci. 125 2011 911 920
170. C.J. Thiele, Z. Li, and A.E. McKee On Trk-the TrkB signal transduction pathway is an increasingly important target in cancer biology Clin. Cancer Res. 15 2009 5962 5967
171. L.J. Thompson, and A.P. Fields BetaII protein kinase C is required for the G2/M phase transition of cell cycle J. Biol. Chem. 271 1996 15045 15053
172. K. Thress, T. Macintyre, H. Wang, D. Whitston, Z.Y. Liu, E. Hoffmann, T. Wang, J.L. Brown, K. Webster, C. Omer, P.E. Zage, L. Zeng, and P.A. Zweidler-McKay Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway Mol. Cancer Ther. 8 2009 1818 1827
173. 2+/calmodulin-dependent protein kinase II J. Biol. Chem. 265 1990 4315 4320
174. (2+)/calmodulin- dependent protein kinase kinase J. Biol. Chem. 277 2002 15813 15818
175. 2+/calmodulin-dependent protein kinase kinase dictates sensitivity to the specific inhibitor, STO-609 J. Biol. Chem. 278 2003 10908 10913
176. D. Toullec, P. Pianetti, H. Coste, P. Bellevergue, T. Grand-Perret, M. Ajakane, V. Baudet, P. Boissin, E. Boursier, and F. Loriolle The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C J. Biol. Chem. 266 1991 15771 15781
177. J.I. Trujillo, J.R. Kiefer, W. Huang, A. Thorarensen, L. Xing, N.L. Caspers, J.E. Day, K.J. Mathis, K.K. Kretzmer, B.A. Reitz, R.A. Weinberg, R.A. Stegeman, A. Wrightstone, L. Christine, R. Compton, and X. Li 2-(6-Phenyl-1H-indazol-3-yl)-1H-benzo[d]imidazoles: design and synthesis of a potent and isoform selective PKC-zeta inhibitor Bioorg. Med. Chem. Lett. 19 2009 908 911
178. M. Uehata, T. Ishizaki, H. Satoh, T. Ono, T. Kawahara, T. Morishita, H. Tamakawa, K. Yamagami, J. Inui, M. Maekawa, and S. Narumiya Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension Nature 389 1997 990 994
179. A.M. van der Linden, S. Wiener, Y.J. You, K. Kim, L. Avery, and P. Sengupta The EGL-4 PKG acts with KIN-29 salt-inducible kinase and protein kinase A to regulate chemoreceptor gene expression and sensory behaviors in Caenorhabditis elegans Genetics 180 2008 1475 1491
180. F. Verkaar, W.M. Blankesteijn, J.F. Smits, and G.J. Zaman Beta-galactosidase enzyme fragment complementation for the measurement of Wnt/beta-catenin signalling FASEB J. 24 2010 1205 1217
181. A. Vogt, A. Tamewitz, J. Skoko, R.P. Sikorski, K.A. Giuliano, and J.S. Lazo The benzo[c]phenanthridine alkaloid, sanguinarine, is a selective, cell-active inhibitor of mitogen-activated protein kinase phosphatase-1 J. Biol. Chem. 280 2005 19078 19086
182. M. Volosin, W. Song, R.D. Almeida, D.R. Kaplan, B.L. Hempstead, and W.J. Friedman Interaction of survival and death signalling in basal forebrain neurons: roles of neurotrophins and proneurotrophins J. Neurosci. 26 2006 7756 7766
183. J. Wagner, P. von Matt, R. Sedrani, R. Albert, N. Cooke, C. Ehrhardt, M. Geiser, G. Rummel, W. Stark, A. Strauss, S.W. Cowan-Jacob, C. Beerli, G. Weckbecker, J.P. Evenou, G. Zenke, and S. Cottens Discovery of 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2, 5-dione (AEB071), a potent and selective inhibitor of protein kinase C isotypes J. Med. Chem. 52 2009 6193 6196
184. M.J. Wallace, P.M. Newton, T. McMahon, J. Connolly, A. Huibers, J. Whistler, and R.O. Messing PKCepsilon regulates behavioral sensitivity, binding and tolerance to the CB1 receptor agonist WIN55,212-2 Neuropsychopharmacology 34 2009 1733 1742
185. J. Wang, M.K. Hancock, J.M. Dudek, and K. Bi Cellular assays for high-throughput screening for modulators of Trk receptor tyrosine kinases Curr. Chem. Genomics 1 2008 27 33
186. T. Wang, D. Yu, and M.L. Lamb Trk kinase inhibitors as new treatments for cancer and pain Expert Opin. Ther. Pat. 19 2009 305 319
187. G.A. Wayman, Y.S. Lee, H. Tokumitsu, A.J. Silva, and T.R. Soderling Calmodulin-kinases: modulators of neuronal development and plasticity Neuron 59 2008 914 931
188. G.A. Wayman, H. Tokumitsu, M.A. Davare, and T.R. Soderling Analysis of CaM-kinase signalling in cells Cell Calcium 50 2011 1 8
189. N.J. Webster, and M.C. Pirrung Small molecule activators of the Trk receptors for neuroprotection BMC Neurosci. 9 Suppl. 2 2008 S1
190. G.R. Wiggin, A. Soloaga, J.M. Foster, V. Murray-Tait, P. Cohen, and J.S. Arthur MSK1 and MSK2 are required for the mitogen- and stress-induced phosphorylation of CREB and ATF1 in fibroblasts Mol. Cell. Biol. 22 2002 2871 2881
191. E.R. Wood, L. Kuyper, K.G. Petrov, R.N. Hunter 3rd, P.A. Harris, and K. Lackey Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles Bioorg. Med. Chem. Lett. 14 2004 953 957
192. P. Workman, P.A. Clarke, F.I. Raynaud, and R.L. van Montfort Drugging the PI3 kinome: from chemical tools to drugs in the clinic Cancer Res. 70 2010 2146 2157
193. T. Yaguchi, M. Saito, Y. Yasuda, T. Kanno, T. Nakano, and T. Nishizaki Higher concentrations of extracellular ATP suppress proliferation of Caco-2 human colonic cancer cells via an unknown receptor involving PKC inhibition Cell. Physiol. Biochem. 26 2010 125 134
194. D.D. Yang, C.Y. Kuan, A.J. Whitmarsh, M. Rincon, T.S. Zheng, R.J. Davis, P. Rakic, and R.A. Flavell Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene Nature 389 1997 865 870
195. P. Yang, Z.Q. Li, L. Song, and Y.Q. Yin Protein kinase C regulates neurite outgrowth in spinal cord neurons Neurosci. Bull. 26 2010 117 125
196. Q. Yang, X. Deng, B. Lu, M. Cameron, C. Fearns, M.P. Patricelli, J.R. Yates 3rd, N.S. Gray, and J.D. Lee Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein Cancer Cell 18 2010 258 267
197. T.C. Yeh, V. Marsh, B.A. Bernat, J. Ballard, H. Colwell, R.J. Evans, J. Parry, D. Smith, B.J. Brandhuber, S. Gross, A. Marlow, B. Hurley, J. Lyssikatos, P.A. Lee, J.D. Winkler, K. Koch, and E. Wallace Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor Clin. Cancer Res. 13 2007 1576 1583
198. R. Yu, S. Mandlekar, T.H. Tan, and A.N. Kong Activation of p38 and c-Jun N-terminal kinase pathways and induction of apoptosis by chelerythrine do not require inhibition of protein kinase C J. Biol. Chem. 275 2000 9612 9619
199. L. Yuan, J.S. Seo, N.S. Kang, S. Keinan, S.E. Steele, G.A. Michelotti, W.C. Wetsel, D.N. Beratan, Y.D. Gong, T.H. Lee, and J. Hong Identification of 3-hydroxy-2-(3-hydroxyphenyl)-4H-1-benzopyran-4-ones as isoform-selective PKC-zeta inhibitors and potential therapeutics for psychostimulant abuse Mol. Biosyst. 5 2009 927 930
200. P.E. Zage, T.C. Graham, L. Zeng, W. Fang, C. Pien, K. Thress, C. Omer, J.L. Brown, and P.A. Zweidler-McKay The selective Trk inhibitor AZ623 inhibits brain-derived neurotrophic factor-mediated neuroblastoma cell proliferation and signalling and is synergistic with topotecan Cancer 117 2011 1321 1391
201. J. Zhang, B. Shen, and A. Lin Novel strategies for inhibition of the p38 MAPK pathway Trends Pharmacol. Sci. 28 2007 286 295
202. J. Zhang, P.L. Yang, and N.S. Gray Targeting cancer with small molecule kinase inhibitors Nat. Rev. Cancer 9 2009 28 39
203. T. Zhang, F. Inesta-Vaquera, M. Niepel, J. Zhang, S.B. Ficarro, T. Machleidt, T. Xie, J.A. Marto, N. Kim, T. Sim, J.D. Laughlin, H. Park, P.V. Lograsso, M. Patricelli, T.K. Nomanbhoy, P.K. Sorger, D.R. Alessi, and N.S. Gray Discovery of potent and selective covalent inhibitors of JNK Chem. Biol. 19 2012 140 154
204. X. Zhang, R. Gao, J. Li, Y. Qi, X. Song, L. Zhao, H. Wang, Y. Pu, and K. Xu A pharmacological activator of AMP-activated protein kinase protects hypoxic neurons in a concentration-dependent manner Neurochem. Res. 35 2010 1281 1289
205. H. Zhong, and J.P. Bowen Recent advances in small molecule inhibitors of VEGFR and EGFR signalling pathways Curr. Top. Med. Chem. 11 2011 1571 1590
206. P. Zhong, W. Liu, Z. Gu, and Z. Yan Serotonin facilitates long-term depression induction in prefrontal cortex via p38 MAPK/Rab5-mediated enhancement of AMPA receptor internalization J. Physiol. 586 2008 4465 4479